ProdromeScan blood test identifies biomarker and biosystem dysfunctions in breast cancer

Prodrome Sciences and Kyoto Prefectural University presented the results from their collaboration on breast cancer biochemistry at the 28th Annual Meeting of The Japanese Breast Cancer Society. The collaboration investigated the biochemical status of women diagnosed with breast cancer before and after surgery and treatment using Prodrome’s ProdromeScan blood testing technology.

Two separate clinical populations involving 300 persons were used to validate the findings. The first population was a cross-sectional study of women prior to treatment and the second study was a longitudinal study that enrolled women at diagnosis and followed them through their treatment protocols.

Consistent with Dr. Goodenowe’s previous research findings, both studies showed that ethanolamine plasmalogen levels, but not phosphatidylethanolamine levels, were lower in women diagnosed with breast cancer. Both studies also showed that women with breast cancer have elevated elongase biomarker activity as measured with ProdromeScan, which was previously only reported in ovarian cancer by Dr. Goodenowe. Interestingly, surgery resulted in the normalization of elongase biomarkers but had no effect on plasmalogen levels. These results indicate that low blood plasmalogens are most likely a pre-existing risk factor for breast cancer whereas elevated elongase activity is related to active breast cancer.

Products sold by Prodrome are intended for research, educational, and informational use only and are not intended to diagnose or treat any disease. You should always seek the advice of a physician or other healthcare provider with any questions you have regarding the diagnosis, cure, treatment, mitigation, or prevention of any disease or other medical condition or impairment of status of your health. Prodrome does not provide medical advice.